
Eleven people in Belgium who had being using the controversial drug domperidone have died, L'Avenir newspaper reported Monday.
Domperidone, which is largely marketed under the name Motilium, is prescribed to combat feelings of nausea.
A recent report by the medical journal "Prescribe" said domperidone was responsible for the deaths of over 200 people in France in 2012.
According to the Federal Agency for Medicines and Health Products (FAMHP), 11 people taking domperidone have died in Belgium.
"With regard to patients treated with medications containing domperidone, 11 deaths were reported to the FAMHP," a statement on the medical professionals' platform MediPlanet said.
Of these, five were reported by medical professionals, meaning "the causal link between the adverse event and base drug domperidone is considered possible," according to the statement.
According to research, domperidone has negative effects on the heart, especially for those over 60.
In September 2014, sales of Motilium 60g suppositories were withdrawn in Belgium, following a decision by the European Commission stating domperidone was a potentially unsafe drug.
GMT 18:06 2018 Tuesday ,09 January
10 migrants dead, dozens missing off Libya coastGMT 22:05 2018 Wednesday ,03 January
US says airstrike kills 2 militants in SomaliaGMT 18:56 2018 Wednesday ,03 January
Philippines prohibits US firm call center from expanding after deadly fireGMT 17:03 2018 Wednesday ,03 January
Severe storm batters western Europe; 1 dead, 15 injuredGMT 16:32 2018 Wednesday ,03 January
Palestinian shot dead in West Bank clashes with Israeli army: ministryGMT 11:49 2018 Wednesday ,03 January
Russian helicopter crashes in Syria, two dead: MoscowGMT 17:22 2017 Thursday ,28 December
10 hurt in Saint Petersburg supermarket bombingGMT 17:49 2017 Wednesday ,27 December
Blast in Saint Petersburg injures four, say officials
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor